ANIP · XBRL financial data

Ani Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANIP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	208	216	316	487	614	883
Cost of revenue	87	—	—	—	—	—
Research and development	16	11	22	34	45	52
Selling, general and administrative	65	84	124	162	250	318
Operating income (loss)	(16)	(40)	(35)	47	1	111
Interest expense	9	12	28	32	34	33
Other income (expense)	(0)	(4)	1	(0)	(4)	2
Income tax expense (benefit)	(3)	(13)	(15)	1	(4)	17
Net income (loss)	(23)	(43)	(48)	19	(19)	78
Earnings per share, basic USD per share	(1.88)	(3.40)	(3.05)	0.86	(1.04)	3.50
Earnings per share, diluted USD per share	(1.88)	(3.40)	(3.05)	0.85	(1.04)	3.32
Weighted average shares, basic millions of shares	12	13	16	18	19	20
Weighted average shares, diluted millions of shares	12	13	16	18	19	21

Fiscal years (ANIP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8	100	48	221	145	286
Accounts receivable	96	129	165	162	222	281
Inventory	61	82	105	111	137	143
Total current assets	170	322	344	520	528	753
Property and equipment, net	41	53	43	45	57	62
Goodwill	4	28	28	28	60	62
Total assets	461	772	760	904	1,284	1,440
Accounts payable	11	23	29	37	46	63
Accrued liabilities	2	8	5	6	14	17
Current portion of long-term debt	13	1	1	1	9	17
Total current liabilities	79	88	99	145	194	278
Long-term debt	172	287	286	285	309	292
Lease liability, non-current	0	1	1	4	4	9
Total liabilities	265	413	422	447	855	900
Accumulated deficit	(5)	(48)	(97)	(80)	(100)	(23)
Total stockholders' equity	196	334	314	433	404	541
Total liabilities and equity	461	772	760	904	1,284	1,440
Common shares outstanding (cover page) millions of shares	—	—	—	—	21	22

Fiscal years (ANIP's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(23)	(43)	(48)	19	(19)	78
Stock-based compensation	13	10	15	21	29	38
Depreciation and amortization	45	47	—	—	—	—
Net cash from operating activities	15	3	(31)	119	64	185
Purchases of property and equipment	6	3	9	9	16	14
Net cash from investing activities	(68)	(105)	(16)	(19)	(405)	(34)
Proceeds from issuing common stock	0	75	0	81	0	0
Share repurchases	2	1	2	5	11	12
Dividends paid	0	0	2	2	2	1
Net cash from financing activities	(1)	195	(5)	67	265	(10)
Net change in cash	—	92	(52)	168	(76)	141

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.